BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD1613 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD1613\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07228364-11156@assetmemo.bio
DTSTAMP:20261121T004554Z
DTSTART;VALUE=DATE:20270522
DTEND;VALUE=DATE:20270523
SUMMARY:AZD1613: Phase 1 readout est. (NCT07228364)
DESCRIPTION:AZD1613\, phase 1\, Autosomal Dominant Polycystic Kidney Diseas
 e.\nStudy: Safety\, Tolerability and Pharmacokinetics of AZD1613 in Adults
  With Autosomal Dominant Polycystic Kidney Disease\nEstimated primary comp
 letion: 22 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 azd1613#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07228364
URL:https://assetmemo.bio/drug/azd1613#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
